Results 11 to 20 of about 28,704 (262)

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma [PDF]

Clinics, 2020
OBJECTIVES: Timolol maleate has been reported to be a safer intraocular pressure (IOP) lowering treatment than latanoprost. The United States Food and Drug Administration approved latanoprostene bunod, a nitric oxide-donating prodrug of latanoprost, for ...
Yulong Wang, Yue Liao, Xin Nie
doaj   +2 more sources

Complete atrioventricular block due to timolol eye drops: a case report and literature review

BMC Pharmacology and Toxicology, 2019
Background Timolol Maleate is a non-selective beta-adrenergic blocker that is commonly used to treat open-angle glaucoma. Despite its topical administration, ophthalmic timolol enters systemic circulation and produces a systemic beta-adrenergic blockade.
Zhuoying Wang, Ian Denys, Feng Chen, Lijie Cai, Xuecui Wang, Daniel R. Kapusta, Yongliang Lv, Juan Gao   +7 more
doaj   +2 more sources

Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial

BMC Cancer, 2022
Introduction Radiation therapy is one of the standard methods in the treatment of breast cancer. Radiotherapy-induced dermatitis (RID) is a common complication of radiotherapy (RT) resulting in less tolerance in RT and even discontinuation of treatment ...
Mohsen Nabi-Meybodi, Adeleh Sahebnasagh, Zahra Hakimi, M. Shabani, Ali Asghar Shakeri, F. Saghafi   +5 more
semanticscholar   +1 more source

Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial.

JAMA dermatology, 2021
Importance Treatment of infantile hemangioma (IH) with topical timolol in the first 2 months of life (early proliferative phase) may prevent further growth and the need for treatment with oral propranolol.
F. Muñoz-Garza, Mônica Rios, E. Roé-Crespo, J. Bernabéu-Wittel, M. T. Montserrat-García, L. Puig, I. Gich, E. Baselga   +7 more
semanticscholar   +1 more source

Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial

Lancet Global Health, 2021
Summary Background Glaucoma is a major cause of sight loss worldwide, with the highest regional prevalence and incidence reported in Africa. The most common low-cost treatment used to control glaucoma is long-term timolol eye drops.
H. Philippin, E. Matayan, Karin M Knoll, Edith Macha, Sia Mbishi, A. Makupa, Cristóvão Matsinhe, V. da Gama, M. Monjane, Awum Joyce Ncheda, Francisco Alcides Mulobuana, Elisante Muna, Nelly Fopoussi, G. Gazzard, A. Marques, P. Shah, D. Macleod, W. Makupa, M. Burton   +18 more
semanticscholar   +1 more source

Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapy.

Materials Science and Engineering C: Materials for Biological Applications, 2021
Topical administration to the eye for the treatment of glaucoma is a convenient route because it increases the patient comfort. Timolol can efficiently diminish the intraocular pressure (IOP) of the eye; however the topical application as a solution of ...
J. C. Cuggino, L. Tártara, L. Gugliotta, S. Palma, C. I. Alvarez Igarzabal   +4 more
semanticscholar   +1 more source

Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: tissue exposures in the rabbit eye.

European journal of pharmaceutics and biopharmaceutics, 2021
Quantitative understanding of pharmacokinetics of topically applied ocular drugs requires more research to further understanding and to eventually allow predictive in silico models to be developed.
A. Fayyaz, Kati-Sisko Vellonen, V. Ranta, Elisa Toropainen, M. Reinisalo, Annika Valtari, J. Puranen, G. D’Amico Ricci, Emma M. Heikkinen, I. Gardner, Marika Ruponen, A. Urtti, M. Jamei, Eva M. del Amo Paez   +13 more
semanticscholar   +1 more source

Combination product of dermal matrix, human mesenchymal stem cells, and timolol promotes diabetic wound healing in mice

Stem Cells Translational Medicine, 2020
Diabetic foot ulcers are a major health care concern with limited effective therapies. Mesenchymal stem cell (MSC)‐based therapies are promising treatment options due to their beneficial effects of immunomodulation, angiogenesis, and other paracrine ...
Hsin-ya Yang, F. Fierro, M. So, Daniel J. Yoon, A. Nguyen, A. Gallegos, M. Bagood, Tomas Rojo-Castro, Alan Alex, Heather Stewart, Marianne Chigbrow, Mohan R. Dasu, T. Peavy, Athena M. Soulika, Jan A. Nolta, R. Isseroff   +15 more
semanticscholar   +1 more source

Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

American journal of ophthalmology-glaucoma, 2018
PURPOSE To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension. DESIGN Double-masked,
J. Serle, L. Katz, E. McLaurin, T. Heah, Nancy Ramirez-Davis, D. Usner, Gary D. Novack, Gary D. Novack, C. Kopczynski   +8 more
semanticscholar   +1 more source

Once-Daily Netarsudil vs Twice-Daily Timolol in Patients with Elevated Intraocular Pressure, the Randomized Phase 3 ROCKET-4 Study.

American journal of ophthalmology-glaucoma, 2019
PURPOSE To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once-daily (QD) and timolol twice-daily (BID). DESIGN Double-masked, randomized, phase 3, non-inferiority study. METHODS Patients with open-angle glaucoma or
A. Khouri, J. Serle, J. Bacharach, D. Usner, R. Lewis, Puiwah Braswell, C. Kopczynski, T. Heah   +7 more
semanticscholar   +1 more source